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P R E V I E W S
Secretory carcinoma is a rare form of
breast cancer, aptly named for the
eosinophilic material that accumulates in
intracellular vacuoles and intercellular
lacunae (Page, 1987). It is a rare tumor,
accounting for fewer than 1% of all
breast cancers, but it is particularly trou-
blesome because it occurs in patients as
young as three years old, and frequently
requires mastectomy and chemotherapy
for treatment. Mastectomy in prepubes-
cent females causes complex psy-
chosocial difficulties in adolescence.
Experience dictates that most early
onset breast cancers are caused by
mutations in genes related to DNA
repair. We were unable to identify muta-
tions in p53, BRCA1, or BRCA2 in secre-
tory carcinomas from two patients, age
five and six, we recently cared for
(unpublished data). In fact, while p53 is
the most commonly altered molecule in
infiltrating ductal carcinoma, it is curious-
ly unaffected in secretory breast cancer
(Maitra et al., 1999).
Tognon and colleagues have detect-
ed the ETV6-NTRK3 fusion gene in 12
(92%) of 13 secretory breast carcino-
mas, but only 1 (2%) of 50 infiltrating
ductal carcinomas. This gene is the
product of a t(12;15)(p13;q25) translo-
cation that fuses the dimerization
domain of a transcriptional regulator
(ETV6) with a membrane receptor tyro-
sine kinase (NTRK3). Prior work con-
firms that the ETV6-NTRK3 fusion pro-
tein can activate the Ras-Mek1 and
PI3K-Akt pathways which are important
for breast cell proliferation and survival.
The methods employed in the current
study are unassailable, including fluo-
rescence in situ hybridization to demon-
strate the ETV6-NTRK3 fusion gene at
the DNA level, sequencing of RT-PCR
products to demonstrate ETV6-NTRK3
expression at the mRNA level, and
immunoprecipitation to confirm ETV6-
NTRK3 expression at the protein level.
In addition, retroviral transduction of the
ETV6-NTRK3 gene into two murine
mammary epithelial cell lines resulted in
transformation and tumorigenesis in
nude mice with preservation of the origi-
nal phenotype.
The suggestion that an alteration in a
single membrane tyrosine kinase recep-
tor is sufficient to transform mammary
epithelial cells should capture our atten-
tion, but the fact that it is the ETV6-
NTRK3 fusion protein that does it should
prompt a double take. The ETV6-NTRK3
fusion gene is associated with infant
fibrosarcoma and congenital mesoblastic
nephroma, two morphologically similar
pediatric mesenchymal tumors with no
epithelial features (Figure 1). The occur-
rence of the same fusion gene in an
epithelial malignancy violates the notion
that specific fusion genes are only asso-
ciated with specific tumor types (Ladanyi
and Bridge, 2000). In fact, fusion genes
are the basis of a growing molecular tax-
onomy for soft tissue tumors, and reports
of the “wrong” fusion gene occurring in
association with a particular histology
prompted one investigator to write,
“Unexpected positive results often attract
more attention and often lead to publica-
tion of case reports. The appearance of
papers reporting unexpected PCR
results that subsequently prove to be irre-
producible has become an increasingly
frequent event in recent years” (Ladanyi
and Bridge, 2000). Given the rigorous
evaluation of the ETV6-NTRK3 fusion
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Figure 1. The t(12;15)(p13;q25) translocation
fuses the ETV6 and NTRK3 genes presumably
resulting in constitutive expression of NTRK3 tyro-
sine kinase activity
The association of this fusion gene with malig-
nancies as morphologically distinct as congeni-
tal mesoblastic nephroma and secretory breast
cancer is notable. One case of acute myeloge-
nous leukemia with a variant of the ETV6-NTK3
fusion gene has been reported (Eguchi et al.,
1999).
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gene in secretory breast carcinoma
described by Tognon and coworkers, it is
highly unlikely that these results will be
“irreproducible.” It must be remembered,
however, that the majority of fusion genes
contributing to the molecular taxonomy of
soft tissue tumors are chimeric transcrip-
tion factors and would be expected to
influence differentiation according to the
types of genes they activate. As a recep-
tor tyrosine kinase capable of activating
the Ras-Mek1 and PI3K-Akt pathways,
which are implicated in many tumor
types, ETV6-NTRK3 appears to be a
more promiscuous oncogene that trans-
forms without interfering with differentia-
tion programs. This is reminiscent of
fusion genes containing the ALK tyrosine
kinase which have been associated with
diseases as morphologically distinct as
inflammatory myofibroblastic tumors and
anaplastic large cell lymphoma
(Lawrence et al., 2000).
Beyond the obvious implications for
understanding carcinogenesis, fusion
genes that lead to constitutive activation
of membrane receptor tyrosine kinases
are of interest for their potential as thera-
peutic targets.The drug imatinib mesylate
(Gleevec) was identified by screening
chemical libraries for compounds with
tyrosine kinase inhibitory activity (Druker,
2002).The most promising candidate was
structurally modified based on knowledge
of structure and activity and then opti-
mized against the platelet-derived growth
factor receptor (PDGFR). The resulting
drug, which is specific for the Abl tyrosine
kinase (of BCR-ABL fame), PDGFR and
c-kit, has revolutionized the treatment of
chronic myelogenous leukemia. Given the
involvement of Trk signaling in malig-
nancies as diverse as congenital meso-
blastic nephroma, infant fibrosarcoma,
melanoma, medullary thyroid cancer,
pancreatic carcinoma, prostate cancer,
and breast carcinoma, it would seem
reasonable to screen chemical libraries
for compounds capable of specifically
inhibiting Trk signaling with the intent of
developing targeted therapies for these
malignancies.
Tognon et al. have unequivocally
demonstrated involvement of the ETV6-
NTRK3 fusion gene in secretory breast
carcinoma, but several questions remain
to be answered. Expression of the ETV6-
NTRK3 fusion gene in pediatric soft tis-
sue tumors is nearly always accompa-
nied by chromosome 11p abnormalities
including partial duplications or chromo-
some 11 multiploidy, both of which affect
the insulin-like growth factor-2 (IGF-2)
locus at 11p15.5 resulting in IGF-2 over-
expression (Knezevich et al., 1998)
(Watanabe et al., 2002). Is this also the
case for secretory breast carcinoma? In
addition, juvenile papillomatosis is a
benign multicystic neoplasm of the
breast characterized by ductal papillo-
matosis and proliferation of atypical
apocrine cells. Because juvenile papillo-
matosis has been reported in associa-
tion with secretory carcinoma (and other
breast cancers) (Rosen et al., 1982), it
would be interesting to know whether the
ETV6-NTRK3 fusion gene can be iden-
tified in this benign lesion. This is not
necessarily to suggest that secretory
carcinoma arises from juvenile papillo-
matosis, but that the two conditions
may represent alternative differentiation
pathways for stem cells expressing the
ETV6-NTRK3 fusion gene. Finally, it has
not been shown unequivocally that it is
the epithelial cells of the secretory carci-
nomas that express ETV6-NTRK3.
Finding the fusion gene in the stromal
cells of this neoplasm would have intrigu-
ing implications for stromal-epithelial
interaction during carcinogenesis or for
epithelial-to-mesenchymal transition dur-
ing progression.
This study has raised many intrigu-
ing questions. It appears that a more
thorough evaluation of the Trk signaling
pathway in breast cancer is in order, as
is a search for other tumor types
expressing the ETV6-NTRK3 fusion
gene. Though congenital mesoblastic
nephroma, infant fibrosarcoma, and
secretory breast carcinoma rarely
metastasize, systemic therapy is some-
times required for cure. Given the high
toxicity of conventional cytotoxic
chemotherapy in very young infants, a
specific NTRK3 tyrosine kinase inhibitor
would be a welcome addition to the ther-
apeutic armamentarium.
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